Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VGX-3100 for HPV-related Vulvar HSIL
NCT03180684Phase 2Completed
- Sponsor
- Inovio Pharmaceuticals, Inc.
- Start
- Aug 2017
- Primary completion
- Jul 2020
- Modality
- Prophylactic Vaccines, DNA Vaccines, Cancer Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of bizalimogene ralaplasmid in vulvar high-grade squamous intraepithelial lesion, sponsored by Inovio Pharmaceuticals, Inc.. Started Aug 2017; status: completed.
02
Drugs
bizalimogene ralaplasmid
03
Conditions
vulvar high-grade squamous intraepithelial lesion
Beyond the preview
Go deeper on NCT03180684.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03180684.